Dr. Sanjay Awasthi Speaks on the Role of Clinical Research in Powering the UAE’s Healthcare Future
Dubai, UAE – 2026 — Avesta Bio, a translational oncology company developing first-in-class therapies targeting cellular stress-response and drug-resistance pathways, was invited by Prof. Humaid Al Shamsi, CEO of the Burjeel Cancer Institute and a leading oncology voice in the United Arab Emirates, to present at WHX Dubai 2026.
Dr. Sanjay Awasthi, Chief Research and Development Officer and Co-Founder of Avesta Bio, participated in the featured panel discussion titled “From Trials to Transformation: How Clinical Research Can Power the UAE.” The session focused on the evolving role of clinical research infrastructure, translational medicine, and international collaboration in advancing the UAE’s position as a global healthcare innovation hub.
WHX Dubai 2026 convened senior healthcare leaders, policymakers, clinicians, and biotechnology innovators from across the Middle East and beyond. The panel highlighted the strategic importance of early-phase clinical trials, regulatory alignment, and public-private partnerships in accelerating access to advanced therapies.
During the discussion, Dr. Awasthi emphasized the importance of mechanistically driven drug development and the need for translational rigor when advancing first-in-class oncology programs. He outlined how targeted approaches to stress-response biology may help address drug resistance and tumor progression, particularly in high-unmet-need patient populations.
“Clinical research is the engine that translates scientific insight into patient impact,” said Dr. Awasthi. “Building strong clinical ecosystems — supported by regulatory clarity, scientific collaboration, and institutional commitment — is essential to transforming healthcare systems and delivering meaningful therapeutic innovation.”
The invitation reflects Avesta Bio’s expanding engagement in the UAE and broader Middle East region as the company advances its lead oncology program toward early-phase clinical development. It also underscores growing international recognition of the importance of stress-response pathway targeting in cancer therapeutics.
About Avesta Bio
Avesta Bio is a translational oncology company developing first-in-class therapies that target fundamental cellular stress-response and drug-resistance pathways. By correcting maladaptive cellular programs implicated in cancer progression, the company aims to deliver safe and effective treatments for patients with high-unmet-need malignancies.
Avesta Bio is advancing its lead program toward Phase I clinical evaluation through strategic global partnerships across research, manufacturing, and clinical development.
For more information, visit: www.avestabio.com